Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

Next Previous
Trial Profile

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098 Administered Orally to Adults With Newly Diagnosed, Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpibectir (Primary) ; Ethionamide (Primary) ; Isoniazid
  • Indications Pulmonary tuberculosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms BETO

Most Recent Events

  • 15 Mar 2026 According to a BioVersys media release, alpibectir (BVL-GSK098) represents a novel approach to overcoming resistance and enhancing the activity of the existing antibiotics ethionamide (Eto) or prothionamide (Pto) for tuberculosis treatment; the fixed-dose combination AlpE received orphan-drug designation from the U.S. FDA in 2023 and from the EMA in 2025.
  • 19 Feb 2026 According to a BioVersys media release, data from the trial were presented in the prestigious New England Journal of Medicine.
  • 19 Feb 2026 Results presented in the BioVersys Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top